CA2533873A1 - Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation - Google Patents

Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation Download PDF

Info

Publication number
CA2533873A1
CA2533873A1 CA002533873A CA2533873A CA2533873A1 CA 2533873 A1 CA2533873 A1 CA 2533873A1 CA 002533873 A CA002533873 A CA 002533873A CA 2533873 A CA2533873 A CA 2533873A CA 2533873 A1 CA2533873 A1 CA 2533873A1
Authority
CA
Canada
Prior art keywords
gmp
biofilm
microbial
aureus
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002533873A
Other languages
English (en)
French (fr)
Inventor
David K.R. Karaolis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2533873A1 publication Critical patent/CA2533873A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CA002533873A 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation Abandoned CA2533873A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49002903P 2003-07-28 2003-07-28
US60/490,029 2003-07-28
PCT/US2004/023498 WO2005030186A2 (en) 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation

Publications (1)

Publication Number Publication Date
CA2533873A1 true CA2533873A1 (en) 2005-04-07

Family

ID=34392905

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002533873A Abandoned CA2533873A1 (en) 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation

Country Status (7)

Country Link
US (1) US8367716B2 (enExample)
EP (1) EP1651242A2 (enExample)
JP (1) JP2007500697A (enExample)
AU (1) AU2004275696B2 (enExample)
CA (1) CA2533873A1 (enExample)
IL (1) IL173065A (enExample)
WO (1) WO2005030186A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2560058C (en) 2004-03-15 2011-10-18 David K.R. Karaolis A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
WO2006073514A2 (en) * 2004-08-25 2006-07-13 Tufts University Compositions, methods and kits for repressing virulence in gram positive bacteria
EP1782826A1 (en) * 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
US8343536B2 (en) 2007-01-25 2013-01-01 Cook Biotech Incorporated Biofilm-inhibiting medical products
GB2463181B (en) 2007-05-14 2013-03-27 Univ New York State Res Found Induction of a physiological dispersion response in bacterial cells in a biofilm
US20090202516A1 (en) 2008-02-08 2009-08-13 Prothera, Inc. Inhibition and treatment of gastrointestinal biofilms
WO2009133560A1 (en) * 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
WO2011003025A1 (en) * 2009-07-01 2011-01-06 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
CN102199183B (zh) * 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
CN101843899B (zh) * 2010-05-24 2012-11-07 中国人民解放军第三军医大学 耐甲氧西林金黄色葡萄球菌(mrsa)重组多亚单位基因工程疫苗及其制备方法
WO2012021554A1 (en) * 2010-08-09 2012-02-16 Yale University Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
AU2013271375B2 (en) 2012-06-08 2018-03-22 Aduro Biotech, Inc. Compositions and methods for cancer immunotherapy
AU2013358892B2 (en) 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
KR102255996B1 (ko) 2012-12-19 2021-05-26 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 포유동물 시클릭 디-뉴클레오티드 신호 경로의 약학적 표적화
CN104152472A (zh) * 2012-12-28 2014-11-19 陶飞 一种双鸟苷酸环化酶基因、载体、工程菌及其应用
JP6153116B2 (ja) * 2013-01-09 2017-06-28 国立大学法人東北大学 トリアゾール連結型環状ジヌクレオチド類縁体
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
ES2822584T3 (es) * 2013-05-03 2021-05-04 Univ California Inducción de dinucleótidos cíclicos del interferón tipo I
US9549944B2 (en) * 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
WO2014189806A1 (en) * 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
PE20160080A1 (es) * 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
JP6462006B2 (ja) 2014-06-04 2019-01-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingのモジュレーターとしての環式ジヌクレオチド
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
CN111263767B (zh) * 2017-08-30 2023-07-18 北京轩义医药科技有限公司 作为干扰素基因调节剂的刺激剂的环状二核苷酸
CN111566119A (zh) 2017-11-10 2020-08-21 武田药品工业有限公司 Sting调节剂化合物以及制备和使用方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020031083A1 (en) * 2018-08-06 2020-02-13 KHAN, Khalid Antimicrobial formulations comprising vancomycin or tobramycin
JP7621974B2 (ja) 2019-05-09 2025-01-27 アリゴス セラピューティクス インコーポレイテッド Stingモジュレータとしての修飾環状ジヌクレオシド化合物
CN114085887A (zh) * 2020-08-25 2022-02-25 中国科学院大连化学物理研究所 一种基于仿生微球的铜绿假单胞菌耐药浓度的检测方法
EP4240488A1 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Antibody drug conjugates
CN114099657B (zh) * 2021-11-04 2022-05-17 暨南大学 一种溶藻弧菌减毒活疫苗及其制备方法与应用
KR102551061B1 (ko) * 2022-05-26 2023-07-03 중앙대학교 산학협력단 Saha를 유효성분으로 포함하는 살모넬라 속 균주에 의한 바이오필름 생성 저해용 조성물
CN118956719B (zh) * 2024-07-31 2025-05-09 武汉市仪泰环境科技有限公司 一种毒性检测中加快微生物挂膜的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268274A (en) * 1989-04-12 1993-12-07 Cetus Corporation Methods and nucleic acid sequences for the expression of the cellulose synthase operon
AU1672492A (en) * 1991-05-03 1992-12-21 University Technologies International Inc. Biofilm reduction method
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
US20020091074A1 (en) * 2000-09-20 2002-07-11 Wooley Richard E. Medical compositions, dressings and methods for treating microbial infections of skin lesions
WO2002074324A1 (en) * 2001-03-15 2002-09-26 The Texas A & M University System Collagen-binding adhesin from staphylococcus epidermidis and method of use
JP2002302404A (ja) * 2001-04-02 2002-10-18 Shiseido Co Ltd 抗菌防黴助剤
US7189351B2 (en) * 2001-10-25 2007-03-13 Spherix Incorporated D-tagatose as an anti-biofilm agent

Also Published As

Publication number Publication date
WO2005030186A3 (en) 2005-07-14
AU2004275696A1 (en) 2005-04-07
EP1651242A2 (en) 2006-05-03
WO2005030186A2 (en) 2005-04-07
AU2004275696B2 (en) 2010-02-18
US8367716B2 (en) 2013-02-05
US20070244059A1 (en) 2007-10-18
JP2007500697A (ja) 2007-01-18
IL173065A (en) 2011-05-31
IL173065A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
AU2004275696B2 (en) Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
Langendonk et al. The building blocks of antimicrobial resistance in Pseudomonas aeruginosa: implications for current resistance-breaking therapies
Mitchell et al. Staphylococcus aureus sigma B-dependent emergence of small-colony variants and biofilm production following exposure to Pseudomonas aeruginosa 4-hydroxy-2-heptylquinoline-N-oxide
Fernández et al. Creeping baselines and adaptive resistance to antibiotics
Arias et al. The rise of the Enterococcus: beyond vancomycin resistance
Van Laar et al. Sublethal concentrations of carbapenems alter cell morphology and genomic expression of Klebsiella pneumoniae biofilms
Russell Mechanisms of bacterial resistance to antibiotics and biocides
Abebe et al. A review on molecular mechanisms of bacterial resistance to antibiotics
Honma et al. Role of a Tannerella forsythia exopolysaccharide synthesis operon in biofilm development
Duménil Type IV pili as a therapeutic target
Espinel et al. Multiple roles of putrescine and spermidine in stress resistance and virulence of Salmonella enterica serovar Typhimurium
Martinez Mechanisms of action and of resistance to quinolones
Hemlata et al. The ever changing face of antibiotic resistance: Prevailing problems and preventive measures
Jolivet‐Gougeon et al. Bacterial Persistence in Biofilms and Antibiotics: Mechanisms Involved
Wagley et al. A proteasome inhibitor produced by Burkholderia pseudomallei modulates intracellular growth
Ravishankar Investigation of antibiofilm and antivirulence activity of 5-fluorocytosine in Escherichia coli
Kanwar et al. Oral Microbiome and Drug Resistance
Rothstein et al. Rifalazil retains activity against rifampin-resistant mutants of Chlamydia pneumoniae
Thapa From Regulation of Secondary Metabolites to Increased Virulence Under Sublethal Dosage of Antibiotics: An Unprecedented Role of Global Regulator, MftR, in Burkholderia Thailandensis
Elkrewi Investigating the prevalence and genetic basis of resistance to the antimicrobial agents bacitracin, nitrofurantoin and silver in key pathogenic bacteria
Krath Investigation of a cryptic aminoglycoside resistance gene in Salmonella Enterica subspecies Enterica Serovar typhimurium
Scoffone et al. Antimicrobial drug efflux pumps in Burkholderia
Kar et al. Quorum sensing mediated attenuation of biofilm formation and virulence traits in Staphylococcus aureus by trigonelline
Surati et al. Antibiotics and Plant-Derived Antimicrobials as an Alternative Source to Control Infections
Ih Mechanisms and PK/PD modelling of MCR-1-induced adaptive resistance in Enterobacteriaceae

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130723